Gilead releases latest data from its liver study

American biotechnology company Gilead Sciences will announce between November 10 and 14,Liver Conference 2023New data on viral hepatitis from the American Association for the Study of Liver Diseases (AASLD).

AnuosinusiGilead’s vice president of clinical research for hepatitis, respiratory and emerging viruses said that at the company, “we look forward to sharing the results of our research with everyone” Latest findings When treating people with this disease VHD (Chronic Hepatitis D)

Network with the wider liver community at the ‘Liver Conference’. ”

“We look forward to sharing our latest findings in treating patients with VHD”

The main findings will be contained in oral expression Primary endpoint outcome assessment of the Phase 2b MYR204 study Herpurux (bulevirtid). This is an investigational therapy used in combination with pegylated interferon alfa-2a (Peginterferon alfa) patients with chronic hepatitis D virus (virtual hard disk).

In turn, they will conduct a comprehensive analysis of this week’s data 96 studies Phase 2b and 3 pivotal trials evaluated the efficacy and safety of bulevirtide monotherapy. On the other hand, biotech companies will also present long-term results (8 years) of ongoing research Wemlidy

(tenofovir alafenamide, TAF) for the treatment of chronic hepatitis B (HBV), which will include two years of efficacy, safety and tolerability data on TAF in pediatric patients with chronic disease.

“Despite significant progress in treating people with AIDS viral hepatitisthere is still much work to be done to improve diagnosis, care and services to meet the unmet needs of people living with viral hepatitis and continue our ongoing commitment to help achieve the following goals: Eliminate HBV and HCV By 2030,” Osinussi concluded.

“Much work remains to be done to improve diagnosis, care and services to address the unmet needs of people living with viral hepatitis”

In the same context, Gilead is known as research leader HDV will provide updated primary endpoint data from the Phase 2b MYR 204 study evaluating the safety and efficacy of bulevirtide in combination with PegIFN (oral LBP-5009). Data on improvements in non-invasive detection will also be provided.this Virological response

Patients receiving bulevirtide for 96 weeks